Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
September 13, 2023 03:01 ET
|
Mainz BioMed NV
Multiple novel mRNA biomarkers identified for potential integration into pivotal FDA PMA clinical trial (ReconAAsense) BERKELEY, Calif. and MAINZ, Germany, Sept. 13, 2023 (GLOBE NEWSWIRE) --...
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
September 05, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
August 29, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
August 22, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
August 15, 2023 03:01 ET
|
Mainz BioMed NV
ColoAlert® Revenue Increases 108% Year Over Year in the First Six Months of 2023 ColoFuture and eAArly Detect Studies on Track to Report Results in September and in Q4, 2023 BERKELEY, Calif. and...
Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
August 01, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
July 18, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, July 18, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“MainzBiomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Secures up to $50M in New Funding
June 29, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, June 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
June 28, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in early...
Mainz Biomed Expands into Romania Through Partnership with Bioclinica
June 20, 2023 03:01 ET
|
Mainz BioMed NV
ColoAlert® will be offered to an addressable market of 6 million patients through 15 laboratories. BERKELEY, Calif. and MAINZ, Germany, June 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV...